INKT Key Statistics, Chart & Performance
The current stock price of INKT is 12.42 USD. In the past month the price decreased by -6.05%. In the past year, price increased by 101.62%.
INKT Latest News, Press Relases and Analysis
INKT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.63 | 394.69B | ||
| AMGN | AMGEN INC | 14.53 | 171.10B | ||
| GILD | GILEAD SCIENCES INC | 14.7 | 149.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.47 | 77.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.51 | 52.52B | ||
| INSM | INSMED INC | N/A | 42.02B | ||
| NTRA | NATERA INC | N/A | 32.01B | ||
| BIIB | BIOGEN INC | 10.4 | 25.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.72 | 21.27B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.26B | ||
| INCY | INCYTE CORP | 14.86 | 18.73B |
Related stock screener links
About INKT
Company Profile
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company is headquartered in New York City, New York and currently employs 23 full-time employees. The company went IPO on 2021-10-15. The firm is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
Company Info
MINK THERAPEUTICS INC
149 Fifth Avenue, Suite 500
New York City NEW YORK US
Employees: 23
Phone: 12129948250
MINK THERAPEUTICS INC / INKT FAQ
Can you describe the business of MINK THERAPEUTICS INC?
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company is headquartered in New York City, New York and currently employs 23 full-time employees. The company went IPO on 2021-10-15. The firm is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
Can you provide the latest stock price for MINK THERAPEUTICS INC?
The current stock price of INKT is 12.42 USD. The price decreased by -1.04% in the last trading session.
What is the dividend status of MINK THERAPEUTICS INC?
INKT does not pay a dividend.
How is the ChartMill rating for MINK THERAPEUTICS INC?
INKT has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the PE ratio for INKT stock?
MINK THERAPEUTICS INC (INKT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.03).
What is MINK THERAPEUTICS INC worth?
MINK THERAPEUTICS INC (INKT) has a market capitalization of 58.25M USD. This makes INKT a Micro Cap stock.
What is the Short Interest ratio of MINK THERAPEUTICS INC (INKT) stock?
The outstanding short interest for MINK THERAPEUTICS INC (INKT) is 1.99% of its float.
INKT Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to INKT. When comparing the yearly performance of all stocks, INKT is one of the better performing stocks in the market, outperforming 92.09% of all stocks.
INKT Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to INKT. INKT may be in some trouble as it scores bad on both profitability and health.
INKT Financial Highlights
Over the last trailing twelve months INKT reported a non-GAAP Earnings per Share(EPS) of -3.03. The EPS increased by 22.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -82.57% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
INKT Forecast & Estimates
8 analysts have analysed INKT and the average price target is 39.78 USD. This implies a price increase of 220.29% is expected in the next year compared to the current price of 12.42.